

Author index to volume 8

- A'Amar O. *See* Bossu E, 67
Aamdal S. *See* Semb KA, 296
Abratt R. *See* Corte-Funes H, 582
Aburano T. *See* Nakajima S, 386
Aggarwal SK. *See* Mehta K, 470; *also* Meara DJ, 988; *also* Muenchen HJ, 323; *also* Muenchen HJ, 784; *also* Wang Y, 853
Albertioni F *et al.* Monitoring of methotrexate and 7-hydroxy-methotrexate in saliva from children with acute lymphoblastic leukemia receiving high-dose consolidation treatment: relation to oral mucositis, 119; *also* Lindemalm S, 445
Allain P. *See* Raymond E, 876
Amano T. *See* Imada T, 1000
Amiri AA. *See* Ravindranath MH, 217
Anderson R. *See* Van Rensburg CEJ, 708
Andoh T. *See* Hamatake M, 637
Andrulis PJ. *See* Muenchen HJ, 323
Animati F. *See* Bigioni M, 845
Araujo CE. *See* Costa LA, 829
Arbuck S. *See* Kudelka AP, 657
Armistead DM. *See* Germann UA, 125
Asakura T *et al.* Drug conjugate of doxorubicin with glutathione is a potent reverser of multidrug resistance in rat hepatoma cells, 199
Atassi G. *See* Guilbaud N, 276; *also* Malonne H, 811; *also* Morris AD, 746
Aviles A *et al.* Epirubicin (CEOP-Bleo) versus idaurubicin (CIOP-Bleo) in treatment of elderly patients with aggressive non-Hodgkin's lymphoma: dose escalation studies, 937
Aydogdu I *et al.* Severe adverse skin reaction to chlorambucil in a patient with chronic lymphocytic leukemia, 468
Ayoub J. *See* Momparler RL, 358
Aziz Z. *See* Pawlicki M, 949
Baba H. *See* Takeuchi H, 778
Bai F. *See* Pei X-H, 231
Barbieri P. *See* Sismondi P, 225
Barrows LR. *See* Pond CD, 336
Bauer PM. *See* Ravindranath MH, 217
Becker M. *See* Fichtner I, 174
Beelen RHJ. *See* Schuurman B, 269
Bélanger K. *See* Momparler RL, 358
Bennis S *et al.* Cellular pharmacology of lipophilic anthracyclines in human tumor cells in culture selected for resistance to doxorubicin, 610
Berthold F. *See* Fichtner I, 174; *also* Fulda S, 34
Bertrán J. *See* Pétriz J, 869
Bibow K. *See* Semb KA, 296
Bigioni M *et al.* Cytotoxic and anti-tumor activity of MEN 10710, a novel alkylating derivative of distamycin, 845
Björkholm M. *See* Eksborg S, 42
Boccardo E. *See* Sismondi P, 225
Boger J. *See* Germann UA, 125
Bojti E. *See* Erdélyi-Tóth V, 603
Bokemeyer C *et al.* A phase II trial of paclitaxel and weekly 24 h infusion of 5-fluorouracil/folinic acid in patients with advanced gastric cancer, 396
Boos J. *See* Wagner A, 419
Borsellino N. *See* Gebbia V, 943
Bossu E *et al.* Determination of the maximal tumour/normal skin ratio after HpD or *m*-THPC administration in hairless mouse (Skh-1) by fluorescence spectroscopy — a non-invasive method, 67
Bösze P. *See* Pawlicki M, 949
Bouffard DY. *See* Momparler RL, 358
Brain E. *See* Soulié P, 763
Bunn J. *See* Kakar SS, 369
Buquet-Fagot C *et al.* Effect of olomoucine, a selective inhibitor of cyclin-dependent kinases, on cell cycle progression in human cancer cell lines, 623; *also* Raymond E, 876
Burbridge M. *See* Guilbaud N, 276
Burger KJ. *See* Färber L, 288; *also* Haus U, 597
Burris HA *et al.* Phase I study with the DNA sequence-specific agent adozelesin, 588
Burt HM. *See* Zhang X, 696
Camoutsis Ch. *See* Psaraki K, 73
Campbell E. *See* Burris HA, 588
Caponigro F *et al.* Protein kinase C: a worthwhile target for anticancer drugs?, 26
Carnino F. *See* Sismondi P, 225
Carotti S. *See* Pinzani P, 767
Caruso M. *See* Colucci G, 257
Cerna C. *See* Izbicke E, 345
Cervellino JC. *See* Costa LA, 829
Chapey C. *See* Bennis S, 610
Chatsipirois D. *See* Färber L, 288
Chen Y-M. *See* Perng R-P, 565
Cheshire PJ. *See* Thompson J, 313
Cinat J. *See* Cinatl Jr J, 958
Cinat Jr J *et al.* Sodium valproate inhibits *in vivo* growth of human neuroblastoma cells, 958
Clark G. *See* Raymond E, 379
Clemens MR. *See* Bokemeyer C, 396
Colucci G *et al.* Dose intensification of mitoxantrone in combination with levofolinic acid, fluorouracil, cyclophosphamide and granulocyte colony stimulating factor support in advanced untreated breast cancer patients. A multicentric phase II study of the Southern Italy Oncology Group, 257; *also* Gebbia V, 943
Coni Molina CM. *See* Costa LA, 829
Cordi AA. *See* Morris AD, 746
Corte-Funes H *et al.* Safety profile of gemcitabine, a novel anticancer agent, in non-small cell lung cancer, 582
Costa LA *et al.* Phase I study of VRCTC-310, a purified phospholipase A₂, purified from snake venom, in patients with refractory cancer. Safety and pharmacokinetic data, 829
Côté S. Activation of the retinoic acid receptor β gene by 5-aza-2'-deoxycytidine in human DLD-1 colon carcinoma cells, 56
Cozma G. *See* Pawlicki M, 949
Cree IA. Individualizing chemotherapy for solid tumors — is there any alternative, 541; *also* Myatt N, 756
Cristina Santos A. *See* Grynberg N, 88
Csörgö M. *See* Erdélyi-Tóth V, 603
Cuellar MT. *See* González-Cid, 529
Cvitkovic E. Role of vindesine as neoadjuvant chemotherapy for non-small cell lung and head and neck cancers, 734; *also* Raymond E, 876; *also* Soulié P, 763
Dakhil SR. *See* Kudelka AP, 657
Danese S. *See* Sismondi P, 225
De Bruijn EA. *See* Dirix LY, 859
de Grip WJ. *See* Hofs HP, 349
de Jong RS *et al.* Fostriecin: a review of the preclinical data, 413
De Marco C. *See* Gornati D, 509
de Valk-Bakker V. *See* Hofs HP, 349
de Vries EGE. *See* de Jong RS, 413
Delia D. *See* Maier JAM, 238

- Delmore JE. *See* Kudelka AP, 657
 Delord JP. *See* Soulié P, 763
 Demopoulos NA. *See* Psaraki K, 73
 Dexter D. *See* Zhang X, 696
 Diaz Maqueo JC. *See* Aviles A, 937
 Dieras VC. *See* Burris HA, 588
 Diez RA. *See* Costa LA, 829
 Dionne J. *See* Momparler RL, 358
 Dirix LY *et al.* *In vitro* toxicity studies with mitomycins and bleomycin on endothelial cells, 859
 Djelloul S. *See* Raymond E, 876
 Doesberg WH. *See* Hofs HP, 349
 Dorr RT. *See* Mayr CA, 245
 Downey G. *See* Kudelka AP, 657
 Drabant S. *See* Erdélyi-Tóth V, 603
 Drechsler S. *See* Färber L, 288
 Driever PH. *See* Cinatl Jr J, 958
 Druyen H. *See* Harstrick A, 391
 Duffy JP. *See* Germann UA, 125
 Durini E. *See* Colucci G, 257
 Durkovic P. *See* Pawlicki M, 949
 Durrant LG. Cancer vaccines, 727

 Earhart RH. *See* Burris HA, 588
 Eberhardt W. *See* Strumberg D, 293
 Echevarria A. *See* Grynberg N, 88
 Eckardt JR. *See* Burris HA, 588
 Edwards CL. *See* Kudelka AP, 649; *also* Kudelka AP, 657
 Egerer G. *See* Goldschmidt H, 436
 Einarsdottir M. *See* Wahlberg P, 522
 Eksborg S *et al.* Plasma pharmacokinetics of idarubicin and its 13-dihydro metabolite — a comparison of bolus versus 2 h infusion during a 3 day course, 42
 Erdélyi-Tóth V *et al.* Pharmacokinetics of panomifene in healthy volunteers at phase I/a study, 603

 Fagerlund E. *See* Eksborg S, 42
 Faivre S *et al.* Paclitaxel (Taxol®)-associated junctional tachycardia, 714; *also* Raymond E, 379
 Färber L *et al.* Treatment of prolonged chemotherapy induced severe thrombocytopenia with recombinant human interleukin-3 — a case report on four cases, 288; *also* Haus U, 597
 Faure P. *See* Bennis S, 610
 Ferraris C. *See* Sismondi P, 225
 Fex G. *See* Wahlberg P, 522
 Fichtner I *et al.* Effects of amifostine (WR-2721, ethylol) on tumor growth and pharmacology of cytotoxic drugs in human xenotransplanted neuroblastomas, 174
 Fields SM. *See* Burris HA, 588
 Fodstad Ø. *See* Semb KA, 296
 Ford PJ. *See* Germann UA, 141
 Forkmann L. *See* Bokemeyer C, 396
 Foss AJE. *See* Myatt N, 756

 Fourche J. *See* Bennis S, 610
 Freedman RS. *See* Kudelka AP, 649; *also* Kudelka AP, 657
 Frei E. *See* Stehle G, 835
 French RC. *See* Caponigro F, 26
 Fücksel G. *See* Färber L, 288
 Fueger R. *See* Kudelka AP, 657
 Fujimaki K. *See* Fujisawa S, 466
 Fujisawa S *et al.* Effect of low-dose 1-hydroxyvitamin D₃ in a patient with myelodysplasia after induction therapy for acute myelocytic leukemia, 466
 Fujita T. *See* Hagiwara A, 182
 Fulda S *et al.* Effects of WR-2721 (amifostine) and its metabolite WR-1065 on the antiproliferative activity of chemotherapeutic agents on neuroblastoma cells *in vitro*, 34

 Gacrama P. *See* Kudelka AP, 657
 Galullo V. *See* Germann UA, 125
 Gantchev TG. Enhancement of etoposide (VP-16) cytotoxicity by enzymatic and photo-dynamically induced oxidative stress, 164
 Garcia EL. *See* Aviles A, 937
 García-López J. *See* Pétriz J, 869
 Garosi VL. *See* Neri B, 459
 Gasparini G. *See* Maier JAM, 238
 Gebbia N. *See* Colucci G, 257; *also* Gebbia V, 943
 Gebbia V *et al.* Cisplatin and epirubicin plus oral lisdamine as first line treatment for metastatic breast cancer: a phase II study of the Southern Italy Oncology Group (GOIM), 943; *also* Colucci G, 257
 Gerli A. *See* Pinzani P, 767
 Germann UA *et al.* Cellular and biochemical characterization of VX-710 as a chemosensitizer: reversal of P-glycoprotein-mediated multidrug resistance *in vitro*, 125; *also* Chemosensitization and drug accumulation effects of VX-710, verapamil, cyclosporin A, MS-209 and GF120918 in multidrug resistant HL60/ADR cells expressing the multidrug resistance-associated protein MRP, 141
 Gespach C. *See* Raymond E, 876
 Giardina G. *See* Sismondi P, 225
 Giotta F. *See* Colucci G, 257; *also* Gebbia V, 943
 Glaser MG. *See* Wedge SR, 92
 Goldschmidt H *et al.* Comparison of oral itasetron with oral ondansetron: results of a double-blind, active-controlled phase II study in chemotherapy-naïve patients receiving moderately emetogenic chemotherapy, 436
 Goldwasser F. *See* Faivre S, 714

 González-Cid M *et al.* Mitotic arrest and anaphase aberrations induced by vinorelbine in hamster cells *in vitro*, 529
 Gornati D *et al.* Modulation of melphalan and cisplatin cytotoxicity in human ovarian cancer cells resistant to alkylating drugs, 509
 Greenberg H. *See* Kudelka AP, 657
 Griffon-Etienne G *et al.* Evaluation of Taxol® in head and neck squamous carcinoma multicellular tumor spheroids, 48
 Groot K. *See* Szepeshazi K, 974
 Grynberg N *et al.* Synthesis and *in vivo* antitumor activity of new heterocyclic derivatives of the 1,3,4-thiadiazolium-2-aminide class, 88
 Guercio E. *See* Sismondi P, 225
 Guilbaud N *et al.* Antitumor activity of S 16020-2 in two orthotopic models of lung cancer, 276; *also* Morris AD, 746
 Guillemin F. *See* Bossu E, 67
 Gyergyay F. *See* Erdélyi-Tóth V, 603

 Hagiwara A *et al.* Selective delivery of 5-fluorouracil (5-FU) to i.p. tissues using 5-FU microspheres in rats, 182; *also* Selective drug delivery to peri-tumoral region and regional lymphatics by local injection of aclarubicin adsorbed on activated carbon particles in patients with breast cancer — a pilot study, 666; *also* Prevention of peritoneal metastasis of cancer with dextran sulfate — an experimental study in mice, 894
 Hajdúch M *et al.* Induction of apoptosis and regression of spontaneous dog melanoma following *in vivo* application of synthetic cyclin dependent kinase inhibitor olomoucine, 1007
 Halmos G. *See* Szepeshazi K, 974
 Hamatake M *et al.* Effects of ICRF-193, a catalytic inhibitor of DNA topoisomerase II, on sister chromatid exchange, 637
 Hanauske A. *See* Raymond E, 379
 Hanuš J. *See* Hajdúch M, 1007
 Hara N. *See* Pei X-H, 231
 Harding MW. *See* Germann UA, 125; *also* Germann UA, 141
 Harstrick A *et al.* Drug interactions of 5-fluorouracil with either cisplatin or lobaplatin — a new, clinically active platinum analog in established human cancer cell lines, 391; *also* Stahl M, 671; *also* Strumberg D, 293
 Hartmann JT. *See* Bokemeyer C, 396

- Hartputuoglu M. *See* Aydogdu I, 468
Hartung G. *See* Stehle G, 835
Hast R. *See* Eksborg S, 42
Haus U *et al.* The effect of recombinant human granulocyte macrophage colony stimulating factor after chemotherapy of various tumors, 597; *also* Färber L, 288
Heene DL. *See* Stehle G, 677; *also* Stehle G, 835
Heidemann A. *See* Harstrick A, 391
Hempel G. *See* Wagner A, 419
Hetland G. Cytotoxic effect of dibutyryl cAMP, phorbol-12-myristate-13-acetate and lipopolysaccharide, but not interferon- γ , on promonocytic cell lines *in vitro*, 618
Hirahara N. *See* Nio Y, 686
Hirvikoski PP *et al.* CNF combination as adjuvant treatment in breast cancer patients is well tolerated, 376
Hisano S. *See* Uchida T, 329
Hlobílková A. *See* Hajdúch M, 1007
Hochhauser D. Modulation of chemosensitivity through altered expression of cell cycle regulatory genes in cancer, 903
Hofs HP *et al.* The effect of ethyldehydroxy-sparsomycin and cisplatin on the intra-cellular glutathione level and glutathione S-transferase activity, 349
Holden JA. *See* Pond CD, 336
Hord M. *See* Kudelka AP, 649
Hosokawa M. *See* Kuramitsu Y, 500; *also* Kuramitsu Y, 886; *also* Kuramitsu Y, 898
Houghton JA. *See* Thompson J, 313
Houghton PJ. *See* Thompson J, 313
Hu Y-P. *See* Bennis S, 610
Huerta-Guzman J. *See* Aviles A, 937
Hungerford JL. *See* Myatt N, 756
Hunter NR. *See* Seong J, 80
Hunter WL. *See* Zhang X, 696
Hunting DJ. *See* Gantchev TG, 164
Idrissi HA. *See* Pawlicki M, 949
Ikada Y. *See* Hagiwara A, 182
Imada T *et al.* *In vitro* combination effect of fluorouracil and cisplatin on the proliferation, morphology and the expression of Ki-67 antigen in human gastric cancer cells, 1000
Imamura M. *See* Kawabata K, 790
Imanishi T. *See* Hagiwara A, 182; *also* Hagiwara A, 666; *also* Hagiwara A, 894
Inganni P. *See* Sismondi P, 225
Inoue M. *See* Nakajima S, 386
Inoue T. *See* Asakura T, 199
Intini C. *See* Neri B, 459
Inutsuka S. *See* Takeuchi H, 778
Ishida R. *See* Hamatake M, 637; *also* Mori H, 482
Ito S. *See* Mori H, 482
Iwasaki M. *See* Watanabe T, 400
Izbicka E *et al.* Activity of TER286 against human tumor colony-forming units, 345; *also* Raymond E, 379
Jackman AL. *See* Takemura Y, 3
Jain PT Human breast cancer cell growth inhibition and deregulation of $[Ca^{2+}]_i$ by estradiol, 283; *also* Antitumor activity of a novel anti-estrogen (analog ID) on human breast cancer cells, 964
Jan M. *See* Guilbaud N, 276; *also* Morris AD, 746
Jassem J. *See* Pawlicki M, 949
Jennes L. *See* Kakar SS, 369
Johansson RT. *See* Hirvikoski PP, 376
Johnson B. *See* Meara DJ, 988
Johnston SRD. Acquired tamoxifen resistance in human breast cancer — potential mechanisms and clinical implications, 911
Jones RC. *See* Ravindranath MH, 217
Jooné G. *See* Van Rensburg CEJ, 708
Kageyama N. *See* Hagiwara A, 666
Kakar SS *et al.* The inhibition of growth and down-regulation of gonadotropin releasing hormone (GnRH) receptor in α T3-1 cells by GnRH agonist, 369
Kakiuch M. *See* Kaneda Y, 702
Kamano T *et al.* Continuous infusion of 5-fluorouracil plus low-dose cisplatin in tumor-bearing mice, 632
Kamm YL. *See* Punt CJA, 454
Kaneda Y *et al.* Antimetastatic effect of synthetic Glu-Ile-Leu-Asp-Val peptide derivatives containing D-amino acids, 702
Kansu E. *See* Pawlicki M, 949
Kanz L. *See* Bokemeyer C, 396
Karıncaoglu Y. *See* Aydogdu I, 468
Kasimir-Bauer S. *See* Stahl M, 671
Kasunic D. *See* Burris HA, 588
Kavallaris M. The role of multidrug resistance-associated protein (MRP) expression in multidrug resistance, 17
Kavanagh JJ. *See* Kudelka AP, 649; *also* Kudelka AP, 657
Kawabata K *et al.* 5-Fluorouracil+cisplatin+mitomycin C is a relatively most effective combination against xenograft lines of human colorectal cancer, 790
Kawasaki K. *See* Kaneda Y, 702
Kawasaki M. *See* Pei X-H, 231
Kaye SB. *See* Caponigro F, 26
Kelley MC. *See* Ravindranath MH, 217
Kempe R. *See* Goldschmidt H, 436
Kim EE. *See* Kudelka AP, 649
Kitaura K. *See* Imada T, 1000
Klaassen U. *See* Strumberg D, 293
Klebovich I. *See* Erdélyi-Tóth V, 603
Klem B. *See* Semb KA, 296
Knudsen H. Application of peptide nucleic acid in cancer therapy, 113
Kobayashi M *et al.* Inhibition of pulmonary metastasis by Z-100, an immunomodulatory lipid-arabinomannan extracted from *Mycobacterium tuberculosis*, in mice inoculated with B16 melanoma, 156; *also* Kuramitsu Y, 500; *also* Kuramitsu Y, 886; *also* Kuramitsu Y, 898
Koda A. *also* Mori H, 482
Koenen HJ. *See* Schuurman B, 269
Kolár Z. *See* Hajdúch M, 1007
Kollmannsberger C. *See* Bokemeyer C, 396
Koomägi R. *See* Volm M, 662; *also* Volm M, 931
Korn MW. *See* Strumberg D, 293
Kornhuber B. *See* Cinatl Jr J, 958
Kosmidis PA. *See* Pawlicki M, 949
Kotchetkov R. *See* Cinatl Jr J, 958
Kralovánszky J. *See* Erdélyi-Tóth V, 603
Kraus-Berthier L. *See* Guilbaud N, 276
Kudelka AP *et al.* A phase II and pharmacokinetic study of enloplatin in patients with platinum refractory advanced ovarian carcinoma, 649; *also* An update of a phase II study of paclitaxel in advanced or recurrent squamous cell cancer of the cervix, 657
Kumpulainen EJ. *See* Hirvikoski PP, 376
Kuramitsu Y *et al.* A new synthetic lipid A analog, ONO-4007, stimulates the production of tumor necrosis factor- α in tumor tissues, resulting in the rejection of transplanted rat hepatoma cells, 500; *also* The mechanism of locally enhanced production of TNF- α in tumor tissues by the administration of a new synthetic lipid A analog, ONO-4007 in hepatoma-bearing rats, 886; *also* Therapeutic effects of a new synthetic lipid A analog, ONO-4007, on rat hepatoma KDH-8 depend on TNF-sensitivity of the tumor cells, 898
Kurbacher CM. *See* Cree LA, 541; *also* Myatt N, 756
Kurita Y. *See* Yokoyama A, 574
Kurteva GP. *See* Pawlicki M, 949
Kusada O. *See* Imada T, 1000
Labrude P. *See* Bossu E, 67

- Lalisang F. *See* Wils JA, 432
 Lallemand F. *See* Buquet-Fagot C, 623
 Lampe CS. *See* Bokemeyer C, 396
 Larripa I. *See* González-Cid, 529
 Latteri MA. *See* Gebbia V, 943
 Lawrence R. *See* Izbicka E, 345
 Lemm M. *See* Fichtner I, 174
 Léonce S. *See* Morris AD, 746
 Libura J. *See* Dirix LY, 859
 Libura M. *See* Dirix LY, 859
 Liliemark J. *See* Lindemalm S, 445
 Lin J-Y. *See* Perng R-P, 565
 Lin S-Y. *See* Perng R-P, 565
 Lindemalm S *et al.* Stability and analysis of 2-chloro-2'-deoxyadenosine, 2-chloro-2'-arabino-fluoro-2'-deoxyadenosine and 2-chloroadenine in human blood plasma, 445
 Linder S. *See* Ljungdahl S, 62
 Lissoni A. *See* Sismondi P, 225
 Ljungdahl S *et al.* Inhibition of the growth of 12V-ras-transformed rat fibroblasts by acetylsalicylic acid correlates with inhibition of NF- κ B, 62
 LoCoco S. *See* Kudelka AP, 657
 Lokiec F. *See* Soulié P, 763
 Lombardi P. *See* Bigioni M, 845
 Lotan C. *See* Pawlicki M, 949
 Louvet C. *See* Raymond E, 876
 Loyer E. *See* Kudelka AP, 657
 Lund B. *See* Corte-Funes H, 582
 Luo X. *See* Thompson J, 313

 Madden TL. *See* Kudelka AP, 649
 Maeda M. *See* Kaneda Y, 702
 Maehara Y. *See* Takeuchi H, 778
 Maggi R. *See* Corte-Funes H, 225
 Maier JAM *et al.* *In vitro* inhibition of endothelial cell growth by the anti-angiogenic drug AGM-1470 (TNP-470) and the anti-endoglin antibody TEC-11, 238
 Maier-Borst W. *See* Stehle G, 677; *also* Stehle G, 835
 Malonne H. DNA Topoisomerases targeting drugs: mechanisms of action and perspectives, 811
 Mangold G. *See* Zhang X, 696
 Mante R. *See* Kudelka AP, 649
 Manzini S. *See* Bigioni M, 845
 Marchal C. *See* Griffon-Etienne G, 48
 Marcus K. *See* Wedge SR, 92
 Martin C. *See* Corte-Funes H, 582
 Maruyama I. *See* Nakajima S, 386
 Masanek U *et al.* Messenger RNA expression of resistance proteins and related factors in human ovarian carcinoma cell lines resistant to doxorubicin, taxol and cisplatin, 189
 Mason VF. *See* Germann UA, 141
 Mason VS. *See* Germann UA, 125
 Matsushita K. *See* Kuramitsu Y, 500; *also* Kuramitsu Y, 886; *also* Kuramitsu Y, 898
 Mattern J. *See* Volm M, 931
 Mayer L. *See* Zhang X, 696
 Mayr CA *et al.* *In vitro* cytotoxicity and DNA damage production in Chinese hamster ovary cells and topoisomerase II inhibition by 2-[2'-(dimethylamino)ethyl]-1,2-dihydro-3H-dibenz[*de,h*]isoquinoline-1,3-diones with substitutions at the 6 and 7 positions (azonafides), 245
 Mayumi T. *See* Kaneda Y, 702
 Mazzei T. *See* Pinzani P, 767
 McQueen T. *See* Mehta K, 470
 Meara DJ *et al.* Role of calcium in modulation of toxicities due to cisplatin and its analogs: a histochemical approach, 988
 Mehta K *et al.* Antiproliferative effect of curcumin (diferuloylmethane) against human breast tumour cell lines, 470
 Merlin J-L. *See* Griffon-Etienne G, 48
 Mester J. *See* Buquet-Fagot C, 623; *also* Raymond E, 876
 Meyer S. *See* Schuurman B, 269
 Mihál V. *See* Hajdúch M, 1007
 Mikami Y. *See* Kamano T, 632
 Milas L. *See* Seong J, 80
 Miles HA. *See* Costa LA, 823
 Milia V. *See* Gebbia V, 943
 Milross CG. *See* Seong J, 80
 Minari Y. *See* Nio Y, 686
 Mini E. *See* Pinzani P, 767
 Miri SM. *See* Ravindranath MH, 217
 Misra HK. *See* Muenchen HJ, 323
 Missel JL. *See* Faivre S, 714; *also* Soulié P, 763
 Mita A. *See* Soulié P, 763
 Mizuno K. *See* Pei X-H, 231
 Mohri H. *See* Fujisawa S, 466
 Momparker LF. *See* Momparker RL, 358
 Momparker RL *et al.* Pilot phase II study on 5-aza-2'-deoxycytidine (Decitabine) in patients with metastatic lung cancer, 358; *also* Côté S, 56
 Montagne M-N. *See* Buquet-Fagot C, 623
 Moody CJ *et al.* Synthesis and cytotoxic activity of indolyl thiazoles, 489
 Mori H *et al.* Irreversible cytotoxic effect of a novel lowly immunosuppressive anti-tumor fluorouridine derivative, UK-21, 482
 Morikawa H. *See* Watanabe T, 400
 Morioka E. *See* Uchida T, 329
 Morris AD *et al.* Eriochrome Black T, structurally related to suramin, inhibits angiogenesis and tumor growth *in vivo*, 746
 Morton DL. *See* Ravindranath MH, 217
 Motomura S. *See* Fujisawa S, 466
 Muenchen HJ. Activation of murine peritoneal macrophages after cisplatin and taxol combination, 784; *also* Enhanced immunostimulation by novel platinum anticancer agents, 323
 Mulder NH. *See* Sleijfer DTh, 107; *also* de Jong RS, 413
 Müller C. *See* Strumberg D, 293
 Murakami N. *See* Nakajima S, 386
 Muranishi S. *See* Hagiwara A, 182
 Myatt N *et al.* The *ex vivo* chemosensitivity profile of choroidal melanoma, 756
 Myer MS. *See* Van Rensburg CEJ, 708

 Nagai H. *See* Mori H, 482
 Nagy A. *See* Szepeshazi K, 974
 Nakagawa S. *See* Kaneda Y, 702
 Nakai Y. *See* Yokoyama A, 574
 Nakajima S *et al.* Therapeutic and imaging capacity of tumor-localizing radiosensitive Mn-porphyrin on SCCVII tumor-bearing C3H/He mice, 386
 Nakanishi Y. *See* Pei X-H, 231
 Nakayama K-i. *See* Mori H, 482
 Nambo MJ. *See* Aviles A, 937
 Nath S. *See* Kakar SS, 369
 Neri B *et al.* Effect of medroxyprogesterone acetate on the quality of life of the oncologic patient: a multicentric cooperative study, 459
 Newlands ES. *See* Wedge SR, 92
 Nielsen PE. *See* Knudsen H, 113
 Niitani H. *See* Yokoyama A, 574
 Nio Y *et al.* A quinolinone derivative, vesnarinone (OPC-8212), significantly inhibits the *in vitro* and *in vivo* growth of human pancreatic cancer cell lines, 686; *also* Kawabata K, 790
 Nishibe M. *See* Kuramitsu Y, 500
 Nosková V. *See* Hajdúch M, 1007
 Notter D. *See* Bossu E, 67
 Novotný R. *See* Hajdúch M, 1007
 O'Sullivan JF. *See* Van Rensburg CEJ, 708
 Obara M. *See* Kuramitsu Y, 500; *also* Kuramitsu Y, 886; *also* Kuramitsu Y, 898
 Ohgaki M. *See* Hagiwara A, 182; *also* Hagiwara A, 666; *also* Hagiwara A, 894
 Ohiro Y. *See* Kuramitsu Y, 500; *also* Kuramitsu Y, 886; *also* Kuramitsu Y, 898
 Ohkawa K. *See* Asakura T, 199
 Ohmori H. *See* Nio Y, 686
 Ohtawa M. *See* Watanabe T, 400
 Okada N. *See* Kaneda Y, 702
 Okubo T. *See* Fujisawa S, 466
 Olas B *et al.* Effect of granulocyte

- colony stimulating factor on pig blood platelets treated with cisplatin *in vitro*, 204
- Osmundsen K. *See* Semb KA, 296
- Oster W. *See* Fulda S, 34
- Ottenheim HCJ. *See* Hofs HP, 349
- Ozcan C. *See* Aydogdu I, 468
- Ozcanu A. *See* Aydogdu I, 468
- Palma C. *See* Bigioni M, 845
- Pantazis P. *See* Mehta K, 470
- Pap É. *See* Erdéyi-Tóth V, 603
- Parache RM. *See* Bossu E, 67
- Pawlicki M *et al.* A multicentre study of recombinant human erythropoietin (epoetin α) in the management of anaemia in cancer patients receiving chemotherapy, 949
- Pazzagli M. *See* Pinzani P, 767
- Pei X-H *et al.* Effect of CPT-11 in combination with other anticancer agents in lung cancer cells, 231
- Pento JT. *See* Jain PT, 964
- Pérez V. *See* Morris AD, 746
- Perng R-P *et al.* A phase I feasibility and pharmacokinetic study of intrapleural paclitaxel in patients with malignant pleural effusions, 565
- Peterson C. *See* Albertioni F, 119
- Pétriz J *et al.* Comparative effect of verapamil, cyclosporin A, and SDZ PSC 833 on rhodamine-123 transport and cell-cycle in vinblastine-resistant Chinese hamster ovary cells overexpressing P-glycoprotein, 869
- Pezzella G. *See* Colucci G, 257
- Pierré A. *See* Guilbaud N, 276; *also* Morris AD, 746
- Pinzani P *et al.* Evaluation of methotrexate sensitivity in human leukemia cell lines by an adenosine triphosphate bioluminescence assay, 767
- Plowman PN. *See* Myatt N, 756
- Pollard RB. *See* Kobayashi M, 156
- Pond CD *et al.* Surface plasmon resonance analysis of topoisomerase I-DNA binding: effect of Mg²⁺ and DNA sequence, 336
- Porteous JK. *See* Wedge SR, 92
- Postmus PE. *See* Tjan-Heijen VCG, 549
- Pouckova P. *See* Cinatl Jr. J, 958
- Pratesi G. *See* Bigioni M, 845
- Psaraki K *et al.* *m*-*N,N*-bis(2-chloroethyl)aminocinnamic acid and four new homo-aza-steroidal esters induce chromosomal abnormalities and affect protein synthesis in human lymphocytes *in vitro*, 73
- Punt CJA *et al.* Weekly chronomodulated 48 h infusion of high-dose 5-fluorouracil modulated by methotrexate and (6S)-leucovorin in advanced colorectal cancer: a phase IB study, 454
- Quietzsch D. *See* Bokemeyer C, 396
- Rajah TT. *See* Jain PT, 964
- Ranjan P *et al.* Cisplatin and interferon- γ treated murine macrophages induce apoptosis in tumor cell lines, 797
- Rask C. *See* Albertioni F, 119
- Rastogi R. *See* Kudelka AP, 649
- Ravindranath MH *et al.* Cellular cancer vaccine induces delayed-type hypersensitivity reaction and augments antibody response to tumor-associated carbohydrate antigens (sialyl Le^a, sialyl Le^x, GD₃ and GM₂) better than soluble lyase cancer vaccine, 217
- Raymond E *et al.* Effects of prolonged versus short-term exposure paclitaxel (Taxol®) on human colony-forming units, 379; *also* Antitumor activity of oxaliplatin in combination with 5-fluorouracil and the thymidylate synthase inhibitor AG337 in human colon, breast and ovarian cancers, 876
- Riccardi F. *See* Colucci G, 257
- Richiardi G. *See* Sismondi P, 225
- Richmond L. *See* Thompson J, 313
- Rigatos GA. *See* Pawlicki M, 949
- Rino Y. *See* Imada T, 1000
- Robert J. *See* Bennis S, 610
- Rodriguez GI. *See* Burris HA, 588
- Roffey JRA. *See* Moody CJ, 489
- Romito S. *See* Colucci G, 257
- Roth A. *See* Pawlicki M, 949
- Rouillon M-H. *See* Guilbaud N, 276
- Rowinsky EK. *See* Raymond E, 379
- Rydell R. *See* Wahlberg P, 522
- Saint-Dizier D. *See* Guilbaud N, 276
- Sakai R. *See* Fujisawa S, 466
- Sakakura C. *See* Hagiwara A, 182; *also* Hagiwara A, 666; *also* Hagiwara A, 894
- Sakata I. *See* Nakajima S, 386
- Salvatore C. *See* Bigioni M, 845
- Salwender H. *See* Goldschmidt H, 436
- Sami SM. *See* Mayr CA, 245
- Sánchez J. *See* Pétriz J, 869
- Sanderson PE. *See* Izbicka E, 345
- Sasaki S. *See* Nio Y, 686
- Sauerbrey A. *See* Stammeler G, 517; *also* Volm M, 662
- Saunders JO. *See* Germann UA, 125
- Sawai K. *See* Hagiwara A, 182; *also* Hagiwara A, 666; *also* Hagiwara A, 894
- Schaaf L. *See* Burris HA, 588
- Schally AV. *See* Szepeshazi K, 974
- Schmid H. *See* Frber L, 288
- Schnabel PC. *See* Pond CD, 336
- Schrenk HH. *See* Stehle G, 677; *also* Stehle G, 835
- Schroeder H. *See* Albertioni F, 119
- Schütt S. *See* Stehle G, 677; *also* Stehle G, 835
- Schuurman B *et al.* Granulocyte macrophage colony stimulating factor pretreatment induces an increase of rat Kupffer cells with enhanced cytotoxicity *in vitro* and prevention of tumor outgrowth *in vivo*, 269
- Scwabe D. *See* Cintel Jr J, 958
- Seeber S. *See* Strumberg D, 293; *also* Harstrick A, 391
- Semb KA *et al.* Zilascorb^{(2)H}, a new reversible protein synthesis inhibitor: clinical study of an oral preparation, 296
- Seong J *et al.* Potentiation of antitumor efficacy of paclitaxel by recombinant tumor necrosis factor- α , 80
- Shaffer DS. *See* Burris HA, 588
- Shigemori N. *See* Nakajima S, 386
- Shin HC. *See* Seong J, 80
- Shirasaka T. *See* Kamano T, 632
- Shirasu M. *See* Hagiwara A, 666; *also* Hagiwara A, 894
- Shlyakhter D. *See* Germann UA, 125; *also* Germann UA, 141
- Shoshan MC. *See* Ljungdahl S, 62
- Siddik ZH. *See* Kudelka AP, 649
- Siddiqui M. *See* Pawlicki M, 949
- Silverstrini R. *See* Gornati D, 509
- Sinn H. *See* Stehle G, 677; *also* Stehle G, 835
- Sismondi P *et al.* Antiemetic efficacy of granisetron in patients with gynecological malignancies, 225
- Skubitz KM. A phase I study of ambulatory continuous infusion paclitaxel, 823
- Sleijfer DTh. Treatment of advanced seminoma: an update, 107
- Sodhi A. *See* Ranjan P, 797
- Soulié P *et al.* Schedule-dependent paclitaxel tolerance/activity: data from a 7 day infusion phase I study with pharmacokinetics in paclitaxel refractory ovarian cancer, 763; *also* Faivre S, 714
- Srivastava A. *See* Ranjan P, 797
- Stahl M *et al.* Down-regulation of topoisomerase II by camptothecin does not prevent additive activity of the topoisomerase II inhibitor etoposide *in vitro*, 671
- Stammeler G. Green tea catechins (EGCG and EGC) have modulating effects on the activity of doxorubicin in drug-resistant cell lines, 265; *also* Deoxycytidine kinase mRNA

- expression in childhood acute lymphoblastic leukemia, 517; *also* Masanek U, 189; *also* Volm M, 662
- Stehle G *et al.* The loading rate determines tumor targeting properties of methotrexate-albumin conjugates in rats, 677; *also* Pharmacokinetics of methotrexate-albumin conjugates in tumor bearing rats, 835
- Stephanou G. *See* Psaraki K, 73
- Stephens MA. *See* Moody CJ, 489
- Stewart CF. *See* Thompson J, 313
- Stratford IJ. *See* Moody CJ, 489
- Strnad M. *See* Hajdúch M, 1007
- Strumberg D *et al.* Phase II trial of continuous oral trofosfamide in patients with advanced colorectal cancer refractory to 5-fluorouracil, 293
- Sugimachi K. *See* Takeuchi H, 778
- Supino R. *See* Bigioni M, 845
- Suzuki F. *See* Kobayashi M, 156
- Számel I. *See* Erdéyi-Tóth V, 603
- Szepeshazi K *et al.* Targeted cytotoxic LH-RH analogs inhibit growth of estrogen independent MXT mouse mammary cancers *in vivo* by decreasing cell proliferation and inducing apoptosis, 974
- Taamma A. *See* Soulié P, 763
- Tachibana K. *See* Uchida T, 329
- Takada K. *See* Asakura T, 199
- Takahashi M. *See* Imada T, 1000
- Takahashi N. *See* Asakura T, 199
- Takahashi T. *See* Hagiwara A, 182; *also* Hagiwara A, 666; *also* Hagiwara A, 894
- Takamura M. *See* Nio Y, 686
- Takayama K. *See* Pei X-H, 231
- Takemoto Y. *See* Hagiwara A, 666
- Takemura T. *See* Nakajima S, 386
- Takemura Y. Folate-based thymidylate synthase inhibitors in cancer chemotherapy, 3
- Takeuchi H *et al.* Potentiation of the cytotoxicity of carboquone by flavone acetic acid combined with hyperthermia, 778
- Talavera A. *See* Aviles A, 937
- Tamura K. *See* Nio Y, 686
- Testa A. *See* Gebbia V, 943
- Theml H. *See* Frber L, 288
- Thompson J *et al.* Efficacy of oral irinotecan against neuroblastoma xenografts, 313
- Thorpe PE. *See* Maier JAM, 238
- Tjan-Heijen VCG *et al.* Dose-intensification of chemotherapy and the role of granulocyte colony stimulating factor and granulocyte macrophage colony stimulating factor in small cell lung cancer, 549
- Todaka T. *See* Watanabe T, 400
- Togawa T. *See* Hagiwara A, 894
- Tomita N. *See* Fujisawa S, 466
- Tornos C. *See* Kudelka AP, 649
- Trandafir L. *See* Soulié P, 763
- Tresukosol D. *See* Kudelka AP, 649
- Trump BF. *See* Jain PT, 283
- Tsujimoto H. *See* Hagiwara A, 182
- Tsuruta N. *See* Pei X-H, 231
- Tsutsumi Y. *See* Kaneda Y, 702
- Tucker GC. *See* Morris AD, 746
- Tunca M. *See* Burris HA, 588
- Turhan O. *See* Aydogdu I, 468
- Uchida T *et al.* Elimination of adult T cell leukemia cells by ultrasound in the presence of porfimer sodium, 329
- Ullrich S. *See* Haus U, 597
- Umbreit J. *See* Kudelka AP, 657
- Valdesi M. *See* Gebbia V, 943
- van Geuns H. *See* Wils JA, 432
- Van Oosterom AT. *See* Dirix LY, 859
- van Rennes H. *See* Hofs HP, 349
- Van Rensburg CEJ *et al.* Novel tetramethylpiperidine-substituted phenazines are potent inhibitors of P-glycoprotein activity in a multidrug resistant cancer cell line, 708
- Vanhoefer U. *See* Harstrick A, 391
- Vannetzel JM. *See* Soulié P, 763
- Vermeulen PB. *See* Dirix LY, 859
- Vigneron C. *See* Bossu E, 67
- Villa R. *See* Gornati D, 509
- Voigt T. *See* Goldschmidt H, 436
- Volm M *et al.* Expression of lung resistance-related protein (LRP) in initial and relapsed childhood acute lymphoblastic leukemia, 662; *also* Expression of lung resistance-related protein (LRP) in non-small cell lung carcinomas of smokers and non-smokers and its predictive value for doxorubicin-resistance, 931; *also* Masanek U, 189; *also* Stammer G, 265, 517
- Von Hoff DD. *See* Izbicka E, 345; *also* Raymond E, 379; *also* Burris HA, 588; *also* Zhang X, 696
- Vreeswijk J. *See* Wils JA, 432
- Wachowicz B. *See* Olas B, 204
- Wachowicz N. *See* Olas B, 204
- Wagener DJTh. *See* Hofs HP, 349; *also* Punt CJA, 454; *also* Tjan-Heijen VCG, 549
- Wagner A *et al.* Trofosfamide: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the oral treatment of cancer, 419
- Wahlberg P *et al.* The additive antiproliferative effect of all-*trans* retinoic acid and interferon- α 2a on human cervical carcinoma cell lines is not associated with increased expression of retinoid receptors, 522
- Wals J. *See* Wils JA, 432
- Wang Y. Effects of cisplatin and taxol on iNOS, gastrin and somatostatin in gastrointestinal toxicity, 853; *also* Meara DJ, 988
- Wasserman E. *See* Cvitkovic E, 734
- Watanabe T *et al.* Effect of SDZ PSC 833 ([3'-keto-Bmt¹]-[Val²]-cyclosporin) on serum protein binding and distribution to blood cells of doxorubicin, vincristine and etoposide *in vitro*, 400
- Wedge SR *et al.* *In vitro* evaluation of temozolomide combined with X-irradiation, 92
- Whang-Peng J. *See* Perng R-P, 565
- Wilke H. *See* Strumberg D, 293; *also* Harstrick A, 391
- Wils JA *et al.* Efficacy of carboplatin plus primary prophylactic filgrastim (granulocyte colony stimulating factor) in relapsed ovarian cancer: a study of the Gynecologic Oncology Group of the Comprehensive Cancer Center Limburg, 432
- Winn R. *See* Kudelka AP, 657
- Wu M-F. *See* Perng R-P, 565
- Wunder A. *See* Stehle G, 677; *also* Stehle G, 835
- Yamamoto A. *See* Hagiwara A, 182
- Yamamoto Y. *See* Kaneda Y, 702
- Yamani J El. *See* Bennis S, 610
- Yamasaki J. *See* Hagiwara A, 182; *also* Hagiwara A, 666; *also* Hagiwara A, 894
- Yokoyama A *et al.* Activity of gemcitabine in the treatment of patients with non-small cell lung cancer: a multicenter phase II study, 574
- Yoneda S. *See* Yokoyama A, 574
- Yuan L. *See* Kuramitsu Y, 500
- Zaffaroni N. *See* Gornati D, 509
- Zamboni WC. *See* Thompson J, 313
- Zelle RE. *See* Germann UA, 125
- Zhang X *et al.* Anti-tumor efficacy and biodistribution of intravenous polymeric micellar paclitaxel, 696
- Zintl F. *See* Stammer G, 517; *also* Volm M, 662
- Zunino F. *See* Bigioni M, 845